Effects of a Novel Aldosterone Synthase Inhibitor for Treatment of Primary Hypertension: Results of a Randomized, Double-Blind, Placebo- and Active-Controlled Phase 2 TrialCALHOUN, David A; WHITE, William B; KRUM, Henry et al.Circulation (New York, N.Y.). 2011, Vol 124, Num 18, pp 1945-1955, issn 0009-7322, 11 p.Article

Effect of Serelaxin on Cardiac, Renal, and Hepatic Biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) Development Program: Correlation With OutcomesMETRA, Marco; COTTER, Gad; DOROBANTU, Maria I et al.Journal of the American College of Cardiology. 2013, Vol 61, Num 2, pp 196-206, issn 0735-1097, 11 p.Article

Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trialTEERLINK, John R; COTTER, Gad; DOROBANTU, Maria I et al.Lancet (British edition). 2013, Vol 381, Num 9860, pp 29-39, issn 0140-6736, 11 p.Article

Pharmacological properties of CGS 35066, a potent and selective endothelin-converting enzyme inhibitor, in conscious ratsTRAPANI, Angelo J; BEIL, Michael E; BRUSEO, Charles W et al.Journal of cardiovascular pharmacology. Supplement. 2000, Vol 36, Num 1, pp S40-S43Conference Paper

Synthesis and biological activity of novel potent endothelin-converting enzyme-1 inhibitorsFIROOZNIA, Fariborz; GUDE, Candido; TRAPANI, Angelo J et al.Bioorganic & medicinal chemistry letters (Print). 2001, Vol 11, Num 3, pp 375-378, issn 0960-894XArticle

Design and synthesis of a potent and selective endothelin-converting enzyme inhibitor, CGS 35066JENG, Arco Y; DE LOMBAERT, Stéphane; BEIL, Michael E et al.Journal of cardiovascular pharmacology. Supplement. 2000, Vol 36, Num 1, pp S36-S39Conference Paper

Synthesis and biological activity of potent heterocyclic thiol-based inhibitors of endothelin-converting enzyme-1FIROOZNIA, Fariborz; GUDE, Candido; CHAN, Kenneth et al.Bioorganic & medicinal chemistry letters (Print). 2002, Vol 12, Num 21, pp 3059-3062, issn 0960-894X, 4 p.Article